Three Strikes, But Not Out Yet, Lilly’s Donanemab Approval Delayed Again

Accelerated Approval Snub Was More Than A Year Ago

The US FDA wants to hold an advisory committee meeting for Lilly’s donanemab in early Alzheimer’s disease, which means approval will now occur after the expected Q1 decision date.

Brain Xray
Donanemab safety and efficacy both are likely topics for the Adcomm • Source: Shutterstock

US Food and Drug Administration approval for Eli Lilly and Company’s donanemab has been delayed for a third time now that the agency has decided to convene a meeting of its Peripheral and Central Nervous System Drugs Advisory Committee (PCNS) to discuss the Phase III TRAILBLAZER-ALZ 2 trial results for the anti-amyloid antibody in early Alzheimer’s disease. Lilly expected approval during the first quarter of 2024 but said on 8 March that this is no longer likely.

Key Takeaways
  • After the US FDA declined to grant accelerated approval for Lilly’s donanemab and pushed out the action date for potential full approval last year, the agency again delayed its decision because it wants to convene an advisory committee meeting.

This is the third time that donanemab’s approval has been pushed back, starting with the FDA’s decision to issue a...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required

More from New Products

Gilead’s Yeytuo, Lilly’s Kisunla Headline CHMP Positive Opinions

 

Yeytuo will have remaining challenges to PrEP to overcome, while Kisunla’s label reflects dosing titration data from a Phase IIIb study to mitigate ARIA-E.

More Pressure on Elevidys As The EU’s CHMP Says ‘No’

 

Just days after Roche stopped shipments of the DMD gene therapy following safety concerns raised by two patient deaths, its EU approval application has hit a block.

Leo Looks To Grow In US After Hand Eczema Cream Approval

 
• By 

The Danish medical dermatology specialist doubles boosts its sales force ahead of the launch of Anzupgo.

Pipeline Watch: Five Approvals And Twelve Phase III Readouts

Pipeline Watch is a weekly snapshot of selected late-stage clinical trial events and approvals announced by pharmaceutical and biotech companies at medical and industry conferences, in financial and company presentations, and in company releases and statements.

More from Scrip

Deal Watch: Novartis Hopes To Ace Inflammatory Disease With Matchpoint Tie-Up

 

Plus deals involving Lilly/Gate Bioscience, Concentra/iTeos, Nicox/Kowa, Ajax/Schrodinger, I-Mab/Bridge Health, Otsuka/Cantargia, JCR/Acumen and more.

More Pressure on Elevidys As The EU’s CHMP Says ‘No’

 

Just days after Roche stopped shipments of the DMD gene therapy following safety concerns raised by two patient deaths, its EU approval application has hit a block.

Executives On The Move: Three New CEOs Among This Week’s Changes

Recent moves in the industry include changes at the top at Trogenix and Quetzal Therapeutics, plus Synendos Therapeutics gains a new CMO from Roche.